P1446A-05

DRUG4 trials

Sponsors

Piramal Enterprises Limited

Conditions

Advanced or Inoperable Malignant Melanoma With BRAF MutationCancerHematologic MalignancyRelapsed/Refractory Chronic Lymphocytic Leukemia (CLL)Solid Tumor

Phase 1

A Multicenter Phase I Clinical Study of a New Compound P1446A-05 in Patients With Advanced Refractory Malignancies

CompletedNCT00772876

Piramal Enterprises LimitedCancer

Start: 2008-12-31End: 2012-05-31Updated: 2012-11-22

A Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies

CompletedNCT00840190

Piramal Enterprises LimitedHematologic Malignancy, Solid Tumor

Start: 2008-12-31End: 2011-09-30Updated: 2012-11-21

Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

SuspendedNCT01841463

Piramal Enterprises LimitedAdvanced or Inoperable Malignant Melanoma With BRAF Mutation

Start: 2013-08-31End: 2016-03-31Target: 100Updated: 2014-09-04

Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

SuspendedNCT02117336

Piramal Enterprises LimitedRelapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Start: 2014-06-30End: 2017-03-31Target: 36Updated: 2014-09-03

Related Papers

Phase I trial of the CDK 4/6 inhibitor, P1446A-05 (voruciclib) in combination with the BRAF inhibitor (BRAFi), vemurafenib in advanced, BRAF-mutant melanoma.

Journal of Clinical Oncology2015-05-208 citations